Phoenix Bio

R&D OVERVIEW

R&D OVERVIEW

Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus

    Hamana, A. Takahashi, Y. Uchida, T. Nishikawa, M. Imamura, M. Chayama, K. Takakura, Y.

    Antiviral Res. 2017 Aug 31;146:130-138.

    Critical role of CREBH-mediated induction of TGF-beta2 by HCV infection in fibrogenic responses in hepatic stellate cells

      Chida, T. Ito, M. Nakashima, K. Kanegae, Y. Aoshima, T. Takabayashi, S. Kawata, K. Nakagawa, Y. Yamamoto, M. Shimano, H. Matsuura, T. Kobayashi, Y. Suda, T. Suzuki, T.

      Hepatology. 2017 Jun 16. doi: 10.1002/hep.29319.

      Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus

        Miyaki, E. Hiraga, N. Imamura, M. Uchida, T.  Kan, H.  Tsuge, M. Abe-Chayama, H. Hayes, C. N. Makokha, G. N. Serikawa, M. Aikata, H. Ochi, H. Ishida, Y. Tateno, C. Ohdan, H. Chayama, K.

        PLoS One. 2017 Mar 2;12(3):e0172412.

        Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology

          Uchida, T. Imamura, M. Kan, H. Hiraga, N. Hayes, C. N. Tsuge, M. Abe-Chayama, H. Aikata, H. Makokha, G. N. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

          J Gen Virol. 2017 Jan 28. doi: 10.1099/jgv.0.000726.

          Protease inhibitor resistance remains even after mutant strains become undetectable using deep sequencing

            Kan, H. Imamura, M. Uchida, T. Hiraga, N. Hayes, C. N. Tsuge, M. Abe, H. Aikata, H. Makokha, G. N. Chowdhury, S. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

            J Infect Dis. 2016 Sep 20. pii: jiw437.

             

            Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy

              DebRoy, S.  Hiraga, N. Imamura, M. Hayes, C. N. Akamatsu, S. Canini, L. Perelson, A. S. Pohl, R. T. Persiani, S. Uprichard, S. L. Tateno, C. Dahari, H. Chayama, K.

              J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.

              Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir andBMS-788329 combination therapy in human hepatocyte chimeric mice

                Uchida, T. Hiraga, N. mamura, M. Yoshimi, S. Kan, H. Miyaki, E. Tsuge, M. Abe, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Ellis, J. D. Chayama, K.

                Virus Res. 2015 Nov 10. pii: S0168-1702(15)30117-9. doi: 10.1016/j.virusres.2015.11.010.

                Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice

                  Kan, H. Hiraga, N. Imamura, M. Hayes, C. N. Uchida, T. Miyaki, E. Tsuge, M. Abe, H. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                  Antivir Ther. 2015 Nov 12. doi: 10.3851/IMP3009.

                  Preclinical characterization andin vivoefficacy of GSK8853, a small molecule inhibitor of the Hepatitis C virus NS4B protein

                    Pouliot, Jeffrey J. Thomson, Michael Xie, Mi Horton, Joseph Johnson, John Krull, David Mathis, Amanda Morikawa, Yoshio Parks, Derek Peterson, Richard, Shimada, Takashi Thomas, Elizabeth Vamathevan, Jessica Van Horn, Stephanie Xiong, Zhiping Hamatake, Robert  Peat, Andrew J.

                    Antimicrob. Agents Chemother. doi:10.1128/AAC.00813-15

                    Prevention of hepatitis C virus infection and spread in human liver chimeric mice by an anti-CD81 monoclonal antibody

                      Ji, C. Liu, Y. Pamulapati, C. Bohini, S. Fertig, G. Schraeml, M. Rubas, W. Brandt, M. Ries, S. Ma, H. Klumpp, K.

                      Hepatology. 2015 Apr;61(4):1136-44.